4.8 Article

The clear cell sarcoma functional genomic landscape

期刊

JOURNAL OF CLINICAL INVESTIGATION
卷 131, 期 15, 页码 -

出版社

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI146301

关键词

-

资金

  1. Cure Childhood Cancer Foundation
  2. Pablove Foundation
  3. Sara's Cure
  4. NIH [R01 MH093595]
  5. Halt Cancer at X Foundation
  6. Pediatric Cancer Program - Intermountain Healthcare and Primary Children's Hospital Foundations
  7. Department of Pediatrics at the University of Utah

向作者/读者索取更多资源

Clear cell sarcoma is a deadly malignancy affecting adolescents and young adults, characterized by frequent amplifications of the MITF locus and chromosomes 7 and 8. Few alterations are shared with other EWSR1-rearranged tumors.
Clear cell sarcoma (CCS) is a deadly malignancy affecting adolescents and young adults. It is characterized by reciprocal translocations resulting in expression of the chimeric EWSR1-ATF1 or EWSR1-CREB1 fusion proteins, driving sarcomagenesis. Besides these characteristics, CCS has remained genomically uncharacterized. Copy number analysis of human CCSs showed frequent amplifications of the MITF locus and chromosomes 7 and 8. Few alterations were shared with Ewing sarcoma or desmoplastic, small round cell tumors, which are other EWSR1-rearranged tumors. Exome sequencing in mouse tumors generated by expression of EWSR1-ATF1 from the Rosa26 locus demonstrated no other repeated pathogenic variants. Additionally, we generated a new CCS mouse by Cre-loxP-induced chromosomal translocation between Ewsr1 and Atf1, resulting in copy number loss of chromosome 6 and chromosome 15 instability, including amplification of a portion syntenic to human chromosome 8, surrounding Myc. Additional experiments in the Rosa26 conditional model demonstrated that Mitf or Myc can contribute to sarcomagenesis. Copy number observations in human tumors and genetic experiments in mice rendered, for the first time to our knowledge, a functional landscape of the CCS genome. These data advance efforts to understand the biology of CCS using innovative models that will eventually allow us to validate preclinical therapies necessary to achieve longer and better survival for young patients with this disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据